CSLLY - CSL announces the availability of HAEGARDA in Canada

CSL Behring Canada, a unit of CSL Limited (CSLLY) announced that HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), is now available throughout Canada.A subcutaneous C1 esterase inhibitor (C1-INH) treatment, HAEGARDA is indicated for the prevention of Hereditary Angioedema ((HAE)) attacks in adolescents and adults.HAE is caused by the deficient or dysfunctional C1-INH, a protein in the blood that helps control inflammation, and is believed to be responsible for edema attacks associated with the disease. HAEGARDA replaces the deficient or dysfunctional C1-INH protein in HAE patients.“At long last, HAEGARDA is now equally available, without restrictions, to adolescent and adult HAE patients across Canada,” noted HAE Canada in a statement.Early this month, CSL Behring announced the completion of the commercialization and license agreement with uniQure for etranacogene dezaparvovec (AMT-061).

For further details see:

CSL announces the availability of HAEGARDA in Canada